Clinical trials: Immune-Related Adverse Events
Nasal Polyps, Asthma, Aspirin-Induced
Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban
The overall aim of the study is to determine the efficacy of oral ifetroban, a novel antagonist of T prostanoid (TP) receptors, as a treatment for patients with aspirin-exacerbated respiratory disease (AERD).
- Conditions
- Nasal Polyps, Asthma, Aspirin-Induced, Aspirin-exacerbated Respiratory Disease, Aspirin-Sensitive Asthma With Nasal Polyps
- Trial name
- NCT03326063
- Testing
- Ifetroban
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Brigham and Women's Hospital
Therapeutic Patient Education, Immune Checkpoint Inhibitors
Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology
The aim of this therapeutic education program is to reduce the apparition of immune-related Adverse Event with patients treated with ICI
- Conditions
- Therapeutic Patient Education, Immune Checkpoint Inhibitors, Melanoma, Advanced Non-small Cell Lung Cancer
- Trial name
- EDHITO (NCT03948724)
- Testing
- Therapeutic education program, Usual Information
- Where
- 9 sites in France
- Volunteers
- 412 people
- Sponsor
- Institut Cancerologie de l'Ouest
Aspirin Exacerbated Respiratory Disease (AERD)
Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease
The primary objective of the study is to determine the safety of oral ifetroban compared to placebo as measured by a > 20% decrease in FEV1 compared to baseline following a dose of Investigational Medicinal Product (IMP) (Study…
- Trial name
- NCT02216357
- Testing
- Ifetroban, Oral Capsule
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Cumberland Pharmaceuticals